Long before China opened its doors to outsourcing, Taiwan was the closest stop to the mainland. And though China has become a force in and of itself in the field, Taiwan has proven it can hold its own.

Companies such as Parexel International ($PRXL), Chiltern, ScinoPharm and Sigma-Aldrich ($SIAL) have found a home on the island, attracted by tax incentives and a streamlined drug-approval process. A solid healthcare system and impressive R&D market have also helped catapult Taiwan to the fourth slot for pharma outsourcing in Asia, behind China, India and South Korea, according to a PricewaterhouseCoopers survey.

The majority of Taiwanese researchers are trained in GCP protocol recognized by the International Conference on Harmonisation. That leads to a level of trust and reliance from foreign regulators looking to gather research from abroad. According to Icon, Taiwan is the second-most active Asian country involved in FDA studies.


Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.